BRCA2 and breast cancer: To validate the increased antitumor effect of irinotecan in olaparib resistant model, we tested the antitumor activity of irinotecan in patient-derived xenograft (PDX) models established from a breast cancer patient with BRCA2 580del4 mutation who acquired resistance to olaparib.